OneStream, Inc.(OS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

OS OneStream, Inc.

休市中 12-05 16:00:00 EST

18.36

-0.37

-1.98%

盘后18.30

-0.06-0.33%

18:54 EST

最高18.99	最低18.16	成交量209.22万
今开18.68	昨收18.73	日振幅4.43%
总市值44.98亿	流通市值40.52亿	总股本2.45亿
成交额3,843万	换手率0.95%	流通股本2.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"OS","market":"US","secType":"STK","nameCN":"OneStream, Inc.","latestPrice":18.36,"timestamp":1764968400000,"preClose":18.73,"halted":0,"volume":2092205,"hourTrading":{"tag":"盘后","latestPrice":18.3,"preClose":18.36,"latestTime":"18:54 EST","volume":71823,"amount":1320584.37,"timestamp":1764978852476},"delay":0,"floatShares":220698554,"shares":244977000,"eps":-0.97803,"marketStatus":"休市中","change":-0.37,"latestTime":"12-05 16:00:00 EST","open":18.68,"high":18.99,"low":18.16,"amount":38431788.96438,"amplitude":0.044314,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.97803,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":18.73,"preHourTrading":{"tag":"盘前","latestPrice":19.05,"preClose":18.73,"latestTime":"09:13 EST","volume":12,"amount":228.200016,"timestamp":1764944023945},"postHourTrading":{"tag":"盘后","latestPrice":18.3,"preClose":18.36,"latestTime":"18:54 EST","volume":71823,"amount":1320584.37,"timestamp":1764978852476},"volumeRatio":1.242038553000022,"impliedVol":0.5929,"impliedVolPercentile":0.44},"requestUrl":"/m/hq/s/OS","defaultTab":"news","newsList":[{"id":"1197163681","title":"OneStream与微软加深战略联盟，推动人工智能在财务办公室的应用与价值","url":"https://stock-news.laohu8.com/highlight/detail?id=1197163681","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197163681?lang=zh_cn&edition=full","pubTime":"2025-11-19 04:06","pubTimestamp":1763496393,"startTime":"0","endTime":"0","summary":"OneStream与微软加深了战略联盟，以加速人工智能在财务办公室的应用和创造价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1629891620.HKD","IE00B7KXQ091.USD","LU2506951958.HKD","LU1935043536.SGD","LU1046421795.USD","LU2065171311.SGD","LU0345770308.USD","LU0157215616.USD","LU2362541273.HKD","BK4503","LU2095319765.USD","LU2133065610.SGD","LU1670627923.USD","LU2125909593.SGD","LU0082616367.USD","IE00BQXX3C00.GBP","LU2023250843.SGD","LU1674673691.USD","LU2286300806.USD","LU1121112475.USD","IE00B4JS1V06.HKD","IE00B3SWFQ91.USD","LU1496350502.SGD","LU1116320901.HKD","BK4581","LU0312595415.SGD","LU2106854487.HKD","LU0726765562.USD","LU2087625088.SGD","LU0757359954.USD","IE00BFSS8Q28.SGD","LU0964807845.USD","LU0965509010.AUD","LU0162691827.USD","LU0894485498.HKD","LU0545039389.USD","LU1571399168.USD","LU0708994859.HKD","IE0004091025.USD","SG9999002224.SGD","IE00BJTD4V19.USD","LU1720051017.SGD","LU2087621335.USD","LU0724617625.USD","LU0511384066.AUD","LU2361045086.USD","LU0158827781.USD","LU1720051108.HKD","LU0672654240.SGD","LU2275660780.HKD","LU1153585028.USD","LU2720916845.USD","LU0689472784.USD","LU1852331112.SGD","LU2168564065.EUR","SG9999001424.SGD","SG9999015986.USD","LU2097829019.USD","LU0949170426.SGD","SG9999015978.USD","SG9999015952.SGD","IE00BKVL7J92.USD","LU2054465674.USD","LU2089284900.SGD","LU2168564222.USD","LU1934455194.USD","SG9999014914.USD","LU0784385840.USD","LU2430703178.SGD","LU0072461881.USD","LU2097344357.USD","LU0267386448.USD","LU1935042991.SGD","LU0444971666.USD","LU1066051811.HKD","LU1582986433.USD","LU0861579265.USD","LU0323240290.USD","IE00BKPKM429.USD","LU0061474960.USD","LU0097036916.USD","IE000KEQY171.SGD","LU1791710582.SGD","LU0889565833.HKD","LU0472753341.HKD","GB00B4LPDJ14.GBP","LU1674673428.USD","IE00BLSP4239.USD","IE00BZ1G4Q59.USD","LU0106261372.USD","LU0949170772.SGD","LU1301847155.USD","LU2089283258.USD","LU0310799852.SGD","IE00B5949003.HKD","LU2028103732.USD","LU2092627202.USD","IE00B19Z9505.USD","LU2360032135.SGD","LU1564329461.SGD","LU1366192091.USD","LU1839511570.USD","LU0154236417.USD","LU2860962120.EUR","LU0210533765.USD","LU0792757196.USD","LU2065169927.USD","LU0894486033.HKD","IE00BYQQ9H92.USD","LU0354030438.USD","IE00BSNM7G36.USD","LU0079474960.USD","SG9999018857.SGD","IE0034235303.USD","LU2361044865.SGD","LU0345774391.USD","LU1261432733.SGD","BK4538","LU2360108059.USD","LU2471134952.CNY","SG9999014880.SGD","LU0061475181.USD","IE00B19Z8X17.USD","LU2592432038.USD","LU0787776722.HKD","LU0323239441.USD","IE0004445239.USD","LU0069063385.USD","LU0171293334.USD","LU1323610961.USD","LU1989772923.USD","LU0289941410.SGD","LU1989772840.SGD","LU0198837287.USD","LU2023251221.USD","LU0912757837.SGD","SGXZ23171101.USD","LU0158827948.USD","BK4585","GB00B4QBRK32.GBP","LU2237443382.USD","LU2458330169.SGD","LU0348723411.USD","LU0640476718.USD","LU1506573853.SGD","LU1732799900.SGD","IE00BJLML261.HKD","LU0823417737.USD","LU1496350171.SGD","GB00BDT5M118.USD","LU0882574139.USD","LU2543165471.USD","LU0057025933.USD","LU0985320562.USD","LU0289960550.SGD","LU0210528500.USD","LU1145028129.USD","SG9999017495.SGD","LU1037948897.HKD","LU2756315664.SGD","LU0476273544.USD","LU2552382058.USD","LU0545562505.USD","IE00B775H168.HKD","LU2552382132.HKD","LU0795875086.SGD","LU2381873111.SGD","LU1032955483.USD","LU2602419157.SGD","LU1691799644.USD","LU0708995401.HKD","LU1244550221.USD","BK4598","LU0345770993.USD","LU2237443549.SGD","IE0001KFT4U8.USD","LU0072462426.USD","LU0868494617.USD","LU0661504455.SGD","LU1435385759.SGD","IE00BFSS7M15.SGD","LU1868836914.USD","LU1861127337.USD","LU2506952097.USD","LU0203201768.USD","LU1037948541.HKD","SG9999014906.USD","LU0302445910.USD","IE00B1BXHZ80.USD","LU0353189680.USD","LU0820562030.AUD","LU0353189763.USD","LU2456880835.USD","LU0823421333.USD","LU0444973449.USD","LU1267930730.SGD","LU1934455277.USD","LU2279689827.SGD","LU2347655073.USD","IE00BDCRKT87.USD","LU1221951046.USD","LU2065171402.SGD","BK4612","LU0342679015.USD","LU1823568750.SGD","IE00BJJMRX11.SGD","LU1119994496.HKD","LU1983260115.SGD","LU0642271901.SGD","LU1280957306.USD","LU1804176565.USD","IE0004086264.USD","BK4525","IE0005OL40V9.USD","BK4588","LU1551013342.USD","IE000YTNTUN2.SGD","BK4532","LU1188199696.SGD","LU1642822529.SGD","LU1196500208.SGD","LU0316494557.USD","LU1868837300.USD","LU0879622024.SGD","LU0256863811.USD","LU1043141396.HKD","LU1935043023.USD","BK4554","LU2347655156.SGD","OS","LU1267930490.SGD","LU0345774631.USD","LU2023250504.SGD","LU2458330243.SGD","LU0466842654.USD","IE00BMPRXR70.SGD","LU1718418525.SGD","IE00BN29S564.USD","LU2237443465.HKD","LU2764262908.HKD","LU1035773651.USD","LU1267930813.SGD","LU2213496289.HKD","IE00B775SV38.USD","LU1791710400.SGD","LU1670711123.USD","LU2506952170.USD","LU0823421416.USD","LU1623119135.USD","LU0276348264.USD","LU0957808578.USD","LU1551013425.SGD","LU1917777945.USD","LU2462157665.USD","SGXZ31699556.SGD","LU0950375773.USD","LU0080751232.USD","SG9999004303.SGD","LU0215105999.USD","LU2242650005.HKD","LU2092937148.SGD","BK4097","LU1074936037.SGD","LU2404859667.USD","LU1564329115.USD","LU0256863902.USD","LU0345768153.USD","LU2237443895.HKD","LU1935042215.USD","LU2360106780.USD","IE0009356076.USD","LU0170899867.USD","LU0528227936.USD","LU2108987350.USD","LU0289961442.SGD","LU2111349929.HKD","LU0234570918.USD","LU2471134879.HKD","LU0823434740.USD","LU0323591593.USD","LU1803068979.SGD","LU2764263039.SGD","LU1235295455.SGD","LU0095938881.EUR","LU1670628061.USD","LU1582987597.SGD","LU1064131342.USD","BK4527","LU0320765059.SGD","LU1244550577.SGD","LU0238689110.USD","LU2491050154.USD","LU0314106906.USD","IE00BK4W5M84.HKD","LU2471134523.USD","LU2463028550.USD","LU1316542783.SGD","LU2420271590.USD","IE00B19Z8W00.USD","IE00BHPRN162.USD","SG9999014567.USD","BK4548","LU0417517546.SGD","LU0689626769.HKD","LU2041044095.USD","LU0683600562.USD","IE00BLSP4452.SGD","LU0124676726.USD","LU1340139317.AUD","SGXZ99366536.SGD","BK4592","LU2417539215.USD","LU1084165304.USD","SG9999000418.SGD","LU1366333091.USD","LU1670710588.SGD","LU2505996509.AUD","LU2210149790.SGD","LU2403377893.USD","LU0345769631.USD","LU2236285917.USD","BK4567","LU2298321311.HKD","LU2433249047.HKD","LU2452424414.USD","LU1267930573.SGD","LU1043141123.HKD","LU1235294995.USD","LU2750360997.AUD","LU0965508806.USD","LU0354030511.USD","LU2750360641.GBP","LU0265550946.USD","LU0456855351.SGD","LU0109392836.USD","LU2362541513.USD","LU2506951875.HKD","LU2461242641.AUD","LU1988902786.USD","BK4550","LU2237957902.USD","LU1803068623.USD","LU1935042488.USD","LU0795875169.SGD","IE00B4YYXB79.USD","LU2505996681.GBP","SGXZ51526630.SGD","LU0029864427.USD","LU1923622614.USD","BK4534","SG9999014898.SGD","LU0820561818.USD","LU1934455863.HKD","LU2211815571.USD","SG9999002232.USD","LU0211327993.USD","LU2092937221.SGD","LU1974910355.USD","IE00BYXW3230.USD","LU1228905540.USD","LU1334329650.SGD","IE0003U64NQ7.SGD","LU0823417653.USD","LU0210536198.USD","SG9999018865.SGD","LU2404859741.USD","LU2191332357.HKD","LU0823434583.USD","LU1815336760.USD","LU1429558221.USD","LU1868836591.USD","LU2168564149.EUR","LU1032466523.USD","LU1989764748.USD","LU0096362180.USD","LU0149725797.USD","LU2265009873.SGD","LU1633808545.USD","LU0690374615.EUR","LU1670711040.USD","LU0094547139.USD","LU1814569148.SGD","IE00BK4W5L77.USD","LU1003077747.HKD","LU2491049909.HKD","LU0175139822.USD","LU0310800379.SGD","LU2023250330.USD","LU0234572021.USD","LU2237443978.SGD","IE000W1ABFV2.USD","LU1868837136.USD","IE00BDRTCR15.USD","SG9999015358.SGD","LU1564329032.USD","LU0289739343.SGD","LU2237443622.USD","SGXZ81514606.USD","LU1721428933.USD","LU1228905037.USD","LU2471134796.USD","LU0957791311.USD","LU2063271972.USD","LU2552382215.SGD","LU0070217475.USD","LU2413666426.HKD","BK4543","LU1989773731.SGD","LU0077335932.USD","LU0426417589.USD","LU1585245621.USD","LU2237957811.SGD","LU0889566641.SGD","LU1548497426.USD","LU2097344431.USD","LU1712237335.SGD","LU0553294199.USD","IE00BMPRXN33.USD","LU0943347566.SGD","IE0004445015.USD","LU1059921491.USD","LU0757359368.USD","IE0034235295.USD","LU2125909247.SGD","LU2361044949.HKD","LU0225283273.USD","BK4528","LU0107464264.USD","LU1989764664.SGD","IE00BKDWB100.SGD","LU2746668974.SGD","IE00BMPRXQ63.HKD","LU0056508442.USD","LU1430594728.SGD","LU0006306889.USD","LU2430703251.USD","LU1035775433.USD","LU0820561909.HKD","LU0109391861.USD","LU2430703095.HKD","LU1732800096.USD","SG9999015341.SGD","MSFT","LU0719512351.SGD","LU2242649171.HKD","LU0061474705.USD","LU0345768740.USD","LU2168564495.EUR","LU1244550494.USD","LU0048584097.USD","LU0690374961.EUR","LU0965509101.SGD","LU1181866309.USD","BK4533","BK4535","IE0034235188.USD","IE00BJJMRY28.SGD","IE00BBT3K403.USD","BK4516","LU0053666078.USD","LU1564329628.SGD","BK4576","LU1914381329.SGD","LU0266013472.USD","LU1778281490.HKD","SG9999014542.SGD","SG9999001077.SGD","LU0784383803.USD","IE00BJTD4N35.SGD","LU2357305700.SGD","LU2083900584.USD","IE00B3S45H60.SGD","LU0251132253.USD","LU0994945656.USD","IE000ITXATA3.USD","SG9999015945.SGD","BK4579","SG9999014575.USD","LU1116320737.USD","LU2077746001.SGD","LU0557290698.USD","LU1670710661.SGD","LU0308772762.SGD","LU1069344957.HKD","IE00B1XK9C88.USD","LU0011850046.USD","LU1582987324.SGD","LU0203202063.USD","LU0960925559.SGD","IE00BQXX3F31.USD","LU2362540622.SGD","LU0738911758.USD","LU1066053197.SGD","LU0788109477.HKD","LU0784385170.HKD","LU1236620834.HKD","LU2746668461.USD","LU0127658192.USD","LU1127390331.HKD","LU0426412945.USD","LU2896262040.SGD","LU0347712357.USD","LU1868836757.USD","LU2065170008.USD","LU0345769128.USD","LU2326559502.SGD","IE00BN8TJ469.HKD","LU2764263203.CNY","LU1697837992.HKD","LU2271345857.HKD","LU2487616109.SGD","IE0009G5SDU7.USD","LU2264538146.SGD","LU2244417387.USD","LU2210150020.SGD","IE00BQXX3D17.EUR","LU0390134368.USD","LU0494093205.USD","LU0314104364.USD","BK4587","LU1232071149.USD","LU2168563687.JPY","IE00BFXG0V08.USD","LU2247934214.USD","LU0081259029.USD","BK4566","LU2237438978.USD","LU0211328371.USD","LU1582986359.USD","LU1221951129.SGD","LU2125154778.USD","LU0784384876.USD","BK4504","IE00BWXC8680.SGD","LU1066051225.USD","BK4577","LU2756315318.SGD","LU1815333072.USD","LU0265550359.USD","LU0965509283.SGD","LU1069347547.HKD","LU0128525929.USD","LU1989763005.USD","LU0187121727.USD","LU2491050071.SGD","LU0096364046.USD","LU1066051498.USD","LU2250418816.HKD","LU2125154935.USD","LU2413666699.HKD","SG9999014559.SGD","LU1236620750.USD","IE00B5TLWC47.USD"],"gpt_icon":0},{"id":"1153324361","title":"包括Blackstone和Hg在内的私募股权公司正在研究对OneStream的潜在收购出价","url":"https://stock-news.laohu8.com/highlight/detail?id=1153324361","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153324361?lang=zh_cn&edition=full","pubTime":"2025-11-06 04:48","pubTimestamp":1762375688,"startTime":"0","endTime":"0","summary":"包括Blackstone和Hg在内的私募股权公司正在研究对OneStream的潜在收购出价","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815336091.USD","LU0757428866.USD","BK4023","OS","BL","BK4097"],"gpt_icon":0},{"id":"2578509299","title":"Os Therapies Incorporated盘中异动 股价大涨6.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578509299","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578509299?lang=zh_cn&edition=full","pubTime":"2025-10-25 03:57","pubTimestamp":1761335849,"startTime":"0","endTime":"0","summary":"北京时间2025年10月25日03时57分，Os Therapies Incorporated股票出现波动，股价快速上涨6.08%。截至发稿，该股报1.92美元/股，成交量27.5883万股，换手率0.82%，振幅4.97%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为0.08%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251025035729a6cc92de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251025035729a6cc92de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OSTX","OS","BK4097"],"gpt_icon":0},{"id":"2576886096","title":"Os Therapies Incorporated盘中异动 快速下跌5.14%报1.76美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576886096","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576886096?lang=zh_cn&edition=full","pubTime":"2025-10-17 22:13","pubTimestamp":1760710391,"startTime":"0","endTime":"0","summary":"北京时间2025年10月17日22时13分，Os Therapies Incorporated股票出现波动，股价急速下挫5.14%。截至发稿，该股报1.76美元/股，成交量33.3201万股，换手率0.99%，振幅6.91%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为0.05%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017221312a4654783&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017221312a4654783&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4097","RANI","OS","BK4139","BK4007","BK4539","OSTX","ARTV"],"gpt_icon":0},{"id":"2575760877","title":"告别繁琐！让AI当你的“生活管家”，是种怎样的体验？","url":"https://stock-news.laohu8.com/highlight/detail?id=2575760877","media":"智东西","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575760877?lang=zh_cn&edition=full","pubTime":"2025-10-16 10:40","pubTimestamp":1760582407,"startTime":"0","endTime":"0","summary":"当下AI圈的热议焦点，往往萦绕于“万亿参数”、“算力突破”等宏大叙事。AI在这里扮演的不是搜索引擎，而是一步到位的服务执行者。在大会现场，AI的演进正经历一场从“控制”到“关怀”的本质蜕变。在陪伴与成长中，AI的角色进化为 “有成长的伙伴”。这也是中国移动董事长杨杰在“AI+”行动中，所提到的“AI+民生保障”的表现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8nUginmB9UB","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["LU2148510915.USD","LU0164865239.USD","BK1152","LU1226287529.USD","LU1634259391.SGD","BK1589","BK4543","LU1951186391.HKD","HK0000252152.HKD","BK4551","HK0000252160.HKD","LU1481107354.HKD","BK4587","LU0149721374.USD","LU1152091168.USD","LU1522347837.USD","OS","SG9999002463.SGD","LU1064130708.USD","BK4528","BK4023","LU1226287875.USD","BK1610","BK4097","LU1226287792.SGD","LU1064131003.USD","BK1506","AI","LU1008478684.HKD","LU0039217434.USD","LU1497734951.SGD","LU1497733557.USD","LU1497733631.SGD","BK1536","LU0880133367.SGD","80883","BK1521","BK4585","LU1226288253.USD","LU1226288170.HKD","BK4588","HK0000500386.USD","00941","LU0067412154.USD","LU0871576103.HKD","LU0531971595.HKD","LU0164880469.USD","LU1634259557.SGD","LU1152091754.HKD"],"gpt_icon":0},{"id":"2574243025","title":"防晒剂龙头创始人逝世","url":"https://stock-news.laohu8.com/highlight/detail?id=2574243025","media":"青眼","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574243025?lang=zh_cn&edition=full","pubTime":"2025-10-11 17:57","pubTimestamp":1760176620,"startTime":"0","endTime":"0","summary":"截至该公告披露日，周久京直接持有科思股份2310万股，占公司股份总额的4.86%，为公司2名实际控制人之一。据悉，周久京逝世前未在科思股份担任任何具体职务。▍截自科思股份公告业绩承压今年上半年营收同比下滑近49%作为“美妆防晒第一股”，科思股份的崛起，却是从合成香料开始。例如，在今年5月的投资者关系文件中，科思股份解释称，2024年业绩下滑的原因，一部分源于防晒剂市场竞争加剧的背景之下，其选择了下调产品价格。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-10-11/doc-inftpmam4915032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EHT","LU0772969993.USD","BK4215","BK4588","LU0742537680.HKD","BK4009","LU1509826696.USD","OS","BK4097","LU0321505868.SGD","AVB","LU0321505439.SGD","LU0731783394.SGD","BK4585","LU1481011671.HKD","LU0731783048.USD","LU1599440770.SGD","LU1481011911.USD","OMC"],"gpt_icon":0},{"id":"2574154301","title":"德达博妥单抗三阴乳腺癌一线治疗新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2574154301","media":"医药地理","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574154301?lang=zh_cn&edition=full","pubTime":"2025-10-09 17:03","pubTimestamp":1760000637,"startTime":"0","endTime":"0","summary":"德达博妥单抗是一款靶向TROP2的DXd抗体偶联药物，由第一三共研发，并由阿斯利康与第一三共共同开发与商业化。目前，德达博妥单抗已在全球35个以上国家和地区获批，用于治疗经既往内分泌治疗及化疗后、不可切除或转移性HR阳性、HER2阴性乳腺癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009171758a6b1b702&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009171758a6b1b702&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4195","BK4585","LU0320765992.SGD","LU2236285917.USD","BK4568","LU1829250122.USD","LU2417539215.USD","OS","LU0889565916.HKD","BK4007","PFS","BK4588","LU0109394709.USD","LU2462157665.USD","BK4097","LU2456880835.USD","BK4211","AZN"],"gpt_icon":0},{"id":"2573939896","title":"第一三共公布TROPION-Breast02 Ⅲ期研究积极的主要结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2573939896","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2573939896?lang=zh_cn&edition=full","pubTime":"2025-10-07 12:19","pubTimestamp":1759810770,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["OS","BK4211","ADC","PFS","BK4097","BK4231","BK4195","BK4080"],"gpt_icon":0},{"id":"2570950855","title":"曝一加氧OS 12 - 15系统存严重漏洞，10月中旬修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2570950855","media":"IT之家","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570950855?lang=zh_cn&edition=full","pubTime":"2025-09-26 21:44","pubTimestamp":1758894249,"startTime":"0","endTime":"0","summary":"IT之家 9 月 26 日消息，安全公司 Rapid7 今天上周发布文章，透露一加氧 OS12-15 系统存在严重安全漏洞，可在未经授权的情况下读取 / 发送短信。目前该漏洞已在一加 8T和一加 10 Pro系统中复现，其他型号也有不同程度的影响。不过氧 OS 11 并没有类似的问题，但 Rapid 7 在 2025 年 5 月就报告了这个漏洞并做多次跟进，一加目前已经承认了问题并提出解决方案，承诺将于 10 月中旬起陆续推送安全补丁，彻底封堵上述漏洞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8myHIZUdfF5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ifeng_tech","symbols":["OS"],"gpt_icon":0},{"id":"2568239777","title":"Os Therapies Incorporated盘中异动 早盘急速跳水6.67%报2.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568239777","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568239777?lang=zh_cn&edition=full","pubTime":"2025-09-18 21:55","pubTimestamp":1758203735,"startTime":"0","endTime":"0","summary":"北京时间2025年09月18日21时55分，Os Therapies Incorporated股票出现波动，股价急速下挫6.67%。截至发稿，该股报2.05美元/股，成交量7.2274万股，换手率0.23%，振幅3.64%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为0.68%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918215535a4cddfc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918215535a4cddfc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4097","OSTX","OS"],"gpt_icon":0},{"id":"2566665256","title":"医保基金监管细则公开征求意见发布；第一三共新生产大楼开工","url":"https://stock-news.laohu8.com/highlight/detail?id=2566665256","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566665256?lang=zh_cn&edition=full","pubTime":"2025-09-09 10:05","pubTimestamp":1757383554,"startTime":"0","endTime":"0","summary":"政策动向《中药生产监督管理专门规定》发布9月8日，国家药监局公布《中药生产监督管理专门规定》（以下简称《规定》），自2026年3月1日起施行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202509093508530127.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509093508530127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK1161","02257","BK4231","OS","BK4080","BK4097"],"gpt_icon":0},{"id":"2565680637","title":"打败“药王”后康方出海数据屡发股价屡跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2565680637","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565680637?lang=zh_cn&edition=full","pubTime":"2025-09-08 22:05","pubTimestamp":1757340300,"startTime":"0","endTime":"0","summary":"康方生物的依沃西单抗作为全球首创PD-1/VEGF双靶点抗肿瘤药，曾在国内试验中击败“药王”K药。9月7日，康方生物发布依沃西单抗海外临床试验最新数据，显示生存获益较此前5月分析结果有明显改善趋势，但9月8日，康方生物股价下跌7.89%，其海外合作伙伴Summit开盘跌17.5%。FDA前临床高级审评员认为，此次发布的数据仍不能说明已达到总生存期（OS）的显著获益，而OS数据是肿瘤药物能否获批上市的最重要指标。9月7日的数据是对5月底全球多中心三期试验结果的更新，5月底数据显示OS数据虽呈改善趋势，但未达到试验标准中的统计学显著性获益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908222513a4bb8f74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908222513a4bb8f74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OS","BK4097","09926"],"gpt_icon":0},{"id":"2565850646","title":"百济神州今日宣布RATIONALE-315研究的最终分析结果和RATIONALE-303研究的长期随访数据显示百泽安（替","url":"https://stock-news.laohu8.com/highlight/detail?id=2565850646","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565850646?lang=zh_cn&edition=full","pubTime":"2025-09-08 19:38","pubTimestamp":1757331495,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","LU1969619763.USD","BK4526","BK1583","BK4139","BK4585","LU1719994722.HKD","BK0239","688235","BK4097","LU0307460666.USD","LU2328871848.SGD","ONC","LU1770034418.SGD","OS","06160","BK1500","LU1251922891.USD","BK1588","LU1303224171.USD","LU0588546209.SGD"],"gpt_icon":0},{"id":"2565794405","title":"中信里昂：维持康方生物(09926.HK)目标价177港元 评级“跑赢大市“","url":"https://stock-news.laohu8.com/highlight/detail?id=2565794405","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565794405?lang=zh_cn&edition=full","pubTime":"2025-09-08 10:00","pubTimestamp":1757296826,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4134","OS","09926","LU1794554557.SGD","LU0348827113.USD","LU0417516571.SGD","LU0561508036.HKD","LU2488822045.USD","LU0417516902.SGD","BK4139","LU0417516738.SGD","LENZ","LU0348766576.USD","LU2778985437.USD","BK1574","LU0634319403.HKD","LU0348825331.USD","IE00B5MMRT66.SGD","BK4097","IE00BPRC5H50.USD","LU2476274720.SGD","BK4007","BK1161","III","LU0348784397.USD","LU0348735423.USD","LU1720050803.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU0348767384.USD","BK4539","LU0348783233.USD","LU2476274308.USD"],"gpt_icon":0},{"id":"2565198595","title":"1400亿广东明星药企，筹资35亿出征全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2565198595","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565198595?lang=zh_cn&edition=full","pubTime":"2025-09-06 17:31","pubTimestamp":1757151073,"startTime":"0","endTime":"0","summary":"一支广东中山的创新药团队，再次募得巨资。9月4日，康方生物公告，已完成新一轮配售，发行新股2355万股，募资近35亿港元。董事会主席、总裁兼CEO夏瑜，及其同事李百勇，也同期出让部分股权。这两年，康方已有三轮募资，筹集金额超过65亿港元。夏瑜领导的这家明星药企，正面临商业爬坡期与临床高投入期的双重压力，其已有7款自研产品上市，加之庞大的后期管线在快速推进，需要持续的资金支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202509063506758557.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509063506758557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0234572021.USD","LU0348767384.USD","LU2361044949.HKD","LU2112291526.USD","SG9999015358.SGD","LU2488822045.USD","LU0122379950.USD","LU2778985437.USD","LU0417516571.SGD","SG9999014542.SGD","LU1917777945.USD","LU0965509010.AUD","LU1069347547.HKD","LU0211331839.USD","SG9999002224.SGD","IE00BPRC5H50.USD","LU1941712264.USD","09926","SG9999014559.SGD","LU0348766576.USD","SG9999014575.USD","LU1035773651.USD","LU1057294990.SGD","LU2476274720.SGD","LU1989772840.SGD","LU0058720904.USD","LU0540923850.HKD","LU1934455863.HKD","LU0320765646.SGD","LU2023250504.SGD","BK4550","LU0965508806.USD","BK4516","LU0965509283.SGD","LU1983299246.USD","BK4007","SG9999014567.USD","IE0002141913.USD","LU1037948541.HKD","LU1794554557.SGD","LU1934455277.USD","MRK","LU1066051811.HKD","LU1989771016.USD","IE00BFTCPJ56.SGD","OS","LU0348825331.USD","LU1974910355.USD","LU1037948897.HKD","LU0070302665.USD"],"gpt_icon":0},{"id":"2562701704","title":"“大牛股”康方生物，核心产品大卖亏损却扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2562701704","media":"时代财经APP","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562701704?lang=zh_cn&edition=full","pubTime":"2025-08-28 12:12","pubTimestamp":1756354374,"startTime":"0","endTime":"0","summary":"财报数据显示，今年上半年，康方生物总收入为14.12亿元，同比增长37.75%。在商业授权收入方面，康方生物在今年上半年已收到990万元。不过，截至今年上半年，康方生物仍处于亏损状态，且亏损金额进一步扩大，为5.88亿元，这一数字在去年同期为亏损2.49亿元。投资者更为关注的是，康方生物核心产品的研发和商业化销售情况，尤其是依沃西在全球市场头对头试验进展。上述相关负责人表示，今年上半年，康方生物在中国市场医院覆盖进一步深化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828125215a4a424fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828125215a4a424fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BN8TJ469.HKD","LU0058720904.USD","LU1941712264.USD","SG9999001176.SGD","LU1093756325.SGD","LU1057294990.SGD","LU1974910355.USD","LU2023250504.SGD","LU2106854487.HKD","IE000M9KFDE8.USD","SG9999015341.SGD","BK4534","LU2324357040.USD","LU1116320737.USD","BK4516","SG9999001440.SGD","IE00BJT1NW94.SGD","LU2487616109.SGD","BK4008","BK4585","OS","LU0208291251.USD","SG9999014542.SGD","LU1066051225.USD","LU1929549753.HKD","LU1934455863.HKD","ALK","BK4007","LU2023250843.SGD","LU0070302665.USD","LU0203347892.USD","LU1023059063.AUD","BK4107","MRK","IE00BBT3K403.USD","LU0106261372.USD","LU1989772923.USD","SG9999014575.USD","LU0965509010.AUD","SG9999013999.USD","SGXZ57979304.SGD","LU1035773651.USD","LU1061106388.HKD","LU1934455277.USD","LU0211331839.USD","LU1585245621.USD","LU1037948541.HKD","LU2468319806.SGD","IE00BSNM7G36.USD","L"],"gpt_icon":0},{"id":"2562709883","title":"康方生物Key data readouts for AK112 to validate","url":"https://stock-news.laohu8.com/highlight/detail?id=2562709883","media":"招银国际","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562709883?lang=zh_cn&edition=full","pubTime":"2025-08-28 11:21","pubTimestamp":1756351315,"startTime":"0","endTime":"0","summary":"AK104和AK112两款药物分别因纳入国家医保目录，在二线及以上的宫颈癌和EGFR突变非小细胞肺癌治疗中推动了销售增长。预计到2026年，随着更多适应症进入NRDL，如一线胃癌、一线宫颈癌和PD-L1阳性非小细胞肺癌等，将进一步加速产品销售。同时，公司计划启动一项针对IO耐药二线肝细胞癌的全球II期注册试验，并探索AK104与AK112联合用药的可能性。此外，Akeso还正在开发HER3ADC和Trop2/Nectin4ADC等早期项目，进一步丰富其研发管线。与此同时，AK104的国际合作潜力也被看好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828114047a4a40388&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828114047a4a40388&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4195","BK4211","OS","BK4097","PFS"],"gpt_icon":1},{"id":"2562775214","title":"欧盟委员会批准百泽安®用于非小细胞肺癌患者新辅助/辅助治疗 最新数据将在2025年世界肺癌大会上公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2562775214","media":"美通社","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562775214?lang=zh_cn&edition=full","pubTime":"2025-08-27 19:20","pubTimestamp":1756293600,"startTime":"0","endTime":"0","summary":"EC的此项批准是基于3期RATIONALE-315研究结果。具体数据将于2025年9月6日至9日在西班牙巴塞罗那举行的国际肺癌研究协会2025年世界肺癌大会上作为最新突破摘要[1]公布。关于RATIONALE-315 RATIONALE-315是一项随机（1:1）、双盲、安慰剂对照、多中心、3期临床试验，评估了百泽安用于453例既往未经治疗、可切除的II期或IIIA期非小细胞肺癌成人患者新辅助/辅助治疗的效果。百泽安已在47个国家和地区获批，全球超过170万例患者接受了治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4760157_ZH60157_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["688235","BK4588","LU1668664300.SGD","LU2360107671.USD","BK1588","BK1161","LU0588546209.SGD","ONC","BK4166","BK4097","EC","06160","TRAE","LU1791807156.HKD","LU1861220207.SGD","DFS","LU1969619763.USD","BK0239","OS","BK1500","LU1861217088.USD","BK4526","BK4201","BK4585","LU2328871848.SGD","BK1583","BK4139","LU0106831901.USD","LU0307460666.USD"],"gpt_icon":0},{"id":"2562789206","title":"Os Therapies Incorporated股价重挫22.98% 市值跌335.59万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562789206","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562789206?lang=zh_cn&edition=full","pubTime":"2025-08-25 21:38","pubTimestamp":1756129089,"startTime":"0","endTime":"0","summary":"北京时间2025年08月25日21时38分，Os Therapies Incorporated股票出现波动，股价快速下挫22.98%。截至发稿，该股报1.91美元/股，成交量12.0121万股，换手率0.38%，振幅4.84%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为0.83%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250825213809a6fa98c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250825213809a6fa98c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OSTX","BK4139","BK4097","OS"],"gpt_icon":0},{"id":"2561409531","title":"Os Therapies Incorporated盘中异动 早盘股价大涨5.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561409531","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561409531?lang=zh_cn&edition=full","pubTime":"2025-08-22 21:33","pubTimestamp":1755869593,"startTime":"0","endTime":"0","summary":"北京时间2025年08月22日21时33分，Os Therapies Incorporated股票出现波动，股价大幅上涨5.83%。截至发稿，该股报2.54美元/股，成交量11.4126万股，换手率0.36%，振幅1.87%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为0.40%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822213313a6f5a449&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822213313a6f5a449&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OS","BK4097"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.onestream.com","stockEarnings":[{"period":"1week","weight":-0.1186},{"period":"1month","weight":-0.087},{"period":"3month","weight":-0.0709},{"period":"6month","weight":-0.3651},{"period":"1year","weight":-0.4045},{"period":"ytd","weight":-0.3562}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"OneStream, Inc.于2021年10月15日在特拉华州注册成立。OneStream提供了一个统一的、支持人工智能和可扩展的软件平台——数字金融云，使首席财务官办公室现代化并增加其战略影响力。他们的平台将核心财务和更广泛的运营数据和流程统一在一个平台内，其解决方案保持了公司财务报告标准的完整性，同时为业务用户提供了重要的运营见解。通过专门为财务构建的嵌入式应用人工智能和机器学习技术，他们的平台自动化和简化了工作流程，加速了分析并提高了预测准确性，使首席财务官办公室能够报告、预测和指导业务绩效。","exchange":"NASDAQ","name":"OneStream, Inc.","nameEN":"OneStream, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OneStream, Inc.(OS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供OneStream, Inc.(OS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"OneStream, Inc.,OS,OneStream, Inc.股票,OneStream, Inc.股票老虎,OneStream, Inc.股票老虎国际,OneStream, Inc.行情,OneStream, Inc.股票行情,OneStream, Inc.股价,OneStream, Inc.股市,OneStream, Inc.股票价格,OneStream, Inc.股票交易,OneStream, Inc.股票购买,OneStream, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OneStream, Inc.(OS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供OneStream, Inc.(OS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}